ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Cephalon 2Q Profit Rises 33%, Adjusted Net Falls On Weak Sales

DOW JONES NEWSWIRES Cephalon Inc.'s (CEPH) second-quarter earnings rose 33% on an investment gain, but the biopharmaceutical company's adjusted profit fell, breaking a long streak, on weak sales for central nervous systems drugs. Sales of central-nervous-system drugs, the company's top-selling category, dropped 4.8%, while the smaller divisions for pain and oncology products saw sales rise 4.4% and 22%, respectively. The company's core profit had increased for three years straight until the latest period. The pace of growth in central-nervous-system drugs had been abating before declining in the latest period, as have the rates for pain and oncology. Cephalon posted a profit of $118.2 million, or $1.34 a share, from $89.1 million, or $1.11 a share, a year earlier. The latest results included a large gain on the fair value of investments, among other items. Excluding them, adjusted earnings fell to $1.62 a share from $2.05. Revenue increased 1.6% to $738.3 million. Analysts expected earnings of $2.06 a share on revenue of $764 million. Gross margin as a percentage of total revenue rose to 83.2% from 76.5%. But costs for research and development jumped 33%. In May, Cephalon agreed to a takeover by Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) for $6.8 billion, which prevailed over a hostile bid from Valeant Pharmaceuticals International Inc. (VRX, VRX.T). In June, U.S. antitrust regulators requested more details about the deal, a development Teva said it expected. Shares were up 0.2% at $80.09 after hours. Through the close, the stock has risen 30% so far this year, better than the wider market. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
07/28/201617:12:36Current Report Filing (8-k)
07/28/201617:00:00Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh...
07/28/201617:00:00Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh...
07/28/201601:00:00Pharming Reports on Financial Results for the First Six Months...
07/26/201608:30:00Progenics Receives $50 Million Milestone Payment Following FDA...
07/22/201617:00:00Toronto Stocks Rise as Earnings Offset Falling Oil and Gold Prices
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/19/201621:40:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201621:02:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201619:19:00Valeant, Progenics Shares Rise on Constipation Drug Approval
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201617:48:00Valeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/18/201601:00:00Pharming Announces Positive Results from Randomized Controlled...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/14/201609:43:00Valeant's Ex-CEO Michael Pearson Sells Nearly $100 Million in...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad